Edwards Lifesciences Corp

For the period ended Mar 31, 2025. Filed May 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 6, 2025

EW$104.01-0.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Condensed Statements of Operations

(in millions, except per share information; unaudited)

	Three Months EndedMarch 31,
	2025	2024
Net sales	$1,412.7	$1,329.9
Cost of sales	301.6	286.9
Gross profit	1,111.1	1,043.0
Selling, general, and administrative expenses	465.7	428.4
Research and development expenses	254.6	256.7
Certain litigation expenses	10.9	8.9
Separation costs (Note 3)	4.2	—
Other operating income	(19.1)	—
Operating income, net	394.8	349.0
Interest income, net	(36.5)	(16.5)
Other non-operating income, net	(2.6)	(5.7)
Income from continuing operations before provision for income taxes	433.9	371.2
Provision for income taxes	70.3	46.3
Net income from continuing operations	363.6	324.9
(Loss) income from discontinued operations, net of tax	(7.2)	26.1
Net income	356.4	351.0
Net loss attributable to noncontrolling interest	(1.6)	(0.9)
Net income attributable to Edwards Lifesciences Corporation	$358.0	$351.9
Share information (Note 13)
Earnings (loss) per share:
Basic
Continuing operations	$0.62	$0.54
Discontinued operations	$(0.01)	$0.04
Basic earnings per share	$0.61	$0.58
Diluted
Continuing operations	$0.62	$0.54
Discontinued operations	$(0.01)	$0.04
Diluted earnings per share	$0.61	$0.58
Weighted-average number of common shares outstanding:
Basic	586.9	601.6
Diluted	587.8	604.1

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.